FemHealth Ventures

FemHealth Ventures is a women's health venture capital firm investing from pre-seed and seed through Series A and later rounds, across digital health and the wider medical technology, diagnostics and therapeutics stack. Its stated aim is to transform women's health by backing groundbreaking health solutions while achieving exceptional financial returns, addressing healthcare gaps that affect half the population.

The firm's differentiator is an intellectual framework it authored rather than borrowed. Published in 2019 as the FemHealth Framework, it defines women's health in three categories: conditions appearing only in women, such as endometriosis, polycystic ovarian syndrome and cervical cancer; mostly in women, such as breast cancer, lupus and multiple sclerosis; and differently in women, such as heart disease, diabetes and asthma. The firm notes the framework has since been widely adopted across the industry. The underlying argument is cellular: every cell in a woman's body carries a different chromosomal makeup than a man's, so the same disease can present differently and require a distinct treatment paradigm. That third category is what separates the thesis from conventional femtech, which concentrates on reproductive health alone.

FemHealth sizes the market using third-party data: women are 50 percent of global healthcare customers per Frost & Sullivan, $500 billion in annual medical expense is attributed to women's healthcare per PitchBook, and more than 4,000 women's health deals have closed. Managing partner Maneesha Ghiya has raised two funds, totalling roughly $52 million in reported proceeds, from Short Hills, New Jersey. Portfolio companies include Imperative Care, Ossium Health, Evommune, Mendaera, Sequel Med Tech, Reunion Neuroscience, AOA Dx and Gynesonics, which has been acquired.